Business
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
SANTA CLARA, Calif., February 12, 2026--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":404,"url":"https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Qcd9s2opb6dyMCLFl2StZw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM4ODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad","width":960,"height":388},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/u8O4ic5g3Y9QYnw7NNgjtA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD04MDg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/a26b14132f647a66bf281375522ab7ad","width":1000,"height":404}},"lazy":false},{"type":"text","content":"Approval expands PD-L1 testing to support treatment decisions with KEYTRUDA® (pembrolizumab)1, 2","length":96,"tagName":"p"},{"type":"text","content":"SANTA CLARA, Calif., February 12, 2026--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved PD-L1 IHC 22C3 pharmDx, Code SK006, as the only FDA-approved companion diagnostic indicated to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC), whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.","length":497,"tagName":"p"},{"type":"text","content":"PD-L1 IHC 22C3 pharmDx, Code SK006, enables pathologists to assess PD-L1 expression at the time of diagnosis, supporting informed treatment decisions in a disease where therapeutic options remain limited for many patients. This approval marks the seventh FDA approved companion diagnostic indication currently available for PD-L1 IHC 22C3 pharmDx, Code SK006, for use with KEYTRUDA.","length":382,"tagName":"p"},{"type":"text","content":"Nina Green, vice president and general manager of Agilent’s Clinical Diagnostics Division, stated: "Delivering effective precision oncology requires close collaboration between diagnostics and therapeutics, and this FDA approval reflects Agilent’s long-standing industry partnership in companion diagnostics. We are proud to enable pathologists to identify patients with EOC who may benefit from immunotherapy. As the first immuno-oncology approval for this disease, this milesto...